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The hemodynamic and electrocardiographic changes in-
duced by left ventriculography and coronary arteriog-
raphy with ioxaglate (a new low osmolality angiographic
contrast agent) were characterized and compared with
the changes induced by a commercial formulation of the
commonly used angiographic contrast agent, diatrizoate
(Renografin-76). Left ventriculography and coronary ar-
teriography were performed in 25 patients utilizing iox-
aglate and in another 25 patients utilizing diatrizoate.
Both agents increased left ventricular end-diastolic pres-
sure and decreased arteriovenous oxygendifference after
left ventriculography, but the magnitude of the increase
caused by ioxaglate was significantly less than that caused
The commonly used radiographic contrast agent for cardiac
and coronary angiography is a 76% solution of the meg-
lumine and sodium salts (66% meglumine and 10% sodium)
of diatrizoic acid. This formula has two fundamental short-
comings that impair its efficacy. The first is its hyperos-
molality. Seventy-six percent meglumine and sodium dia-
trizoate (which contains 37% iodine) has an osmolality of
1,600 mosmollkg, which is roughly five times the osmolality
of plasma. The second shortcoming is a transient myocardial
depressant action that does not appear to be related to the
osmolality of the solution (1-8). Together these two short-
comings cause an increase in left ventricular filling pressures
during the period immediately after injection of contrast
agent.
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by diatrizoate (changes in left ventricular end-diastolic
pressure was 5.3 ± 1.3 mm Hg with ioxaglate and 9.5
± 1.5 mm Hg with diatrizoate [p < 0.02]). Change in
arteriovenous oxygendifferencewas - 0.33 ± 0.19 mIll00
ml with ioxaglate and -0.85 ± 0.13 ml/l00 ml with
diatrizoate (p < 0.05).
Both agents were well tolerated when used for coro-
nary arteriography with no adverse events occurring in
either group. Ioxaglate is a well tolerated cardiac an-
giographic contrast agent that produces less hemody-
namic disturbance than diatrizoate. Accordingly, it may
be particularly well suited to use in patients with im-
paired left ventricular function.
In most patients, this increase is not clinically significant
and does not produce symptoms or compromise the extent
or quality of the diagnostic study. In other patients, how-
ever, particularly those with impaired left ventricular func-
tion or severe valvular disease, the degree of contrast agent-
induced elevation of left ventricular filling pressures is un-
acceptable and may cause pulmonary edema. In such pa-
tients, the hemodynamic consequences of the contrast agent
administration may require abbreviation of, or even pre-
clude, the angiographic portion of the study. Paradoxically,
those patients who are least able to tolerate the insult of
contrast agent injection frequently have cardiac disease that
is so severe and complex that multiple contrast injections
are necessary to define the situation completely. A contrast
agent that causes less hemodynamic disturbance would be
particularly useful for conducting studies in these patients.
During the past decade, there has been an active search
for new radiographic contrast agent molecules. A consistent
effort has been made to increase the quantity of iodine per
osmotically active particle. Ioxaglate is a low osmolality
radiographic contrast agent that was synthesized in 1973
(9). It has been in active clinical use in Europe and South
America since 1978. In contrast to diatrizoate, which has
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three iodine atoms per two osmotically active particles, iox-
aglate has six iodine atoms per two osmotically active par-
ticles. The clinically used formulation of ioxaglate is a 59%
solution that contains 32% iodine and has an osmolality of
600 mosmol/kg. A solution containing 37% iodine, which
would be equivalent in iodine concentration to 76% diatri-
zoate, is too viscous for clinical use.
Although its myocardial depressant properties appear to
be similar to diatrizoate (10), the lower osmolality of the
ioxaglate formulation should cause it to produce less hemo-
dynamic disturbance than other preparations with higher
osmolality. In order to test this hypothesis, we have ex-
amined the hemodynamic response to left ventriculography
with both 59% ioxaglate and a commonly used formulation
of 76% diatrizoate.
Methods
Studypatients. Studies were performed on 50 adult pa-
tients undergoing routine diagnostic cardiac catheterization
with left ventriculography and coronary arteriography. All
patients were studied for the evaluation of known or sus-
pected coronary disease. Informed consent was obtained
from each patient.
Cardiac catheterization procedure. Standard 7 French
fluid-filled catheters were placed in the left and right ven-
tricles and baseline left and right ventricular pressures were
recorded. Arteriovenous oxygen difference measured by ox-
imetry (Instrumentation Laboratory model 282 Co-oxime-
ter) was used as an estimate of cardiac output.
After baseline pressure and cardiac output measure-
ments, left ventriculography was performed using either
ioxaglate or diatrizoate as a contrast agent. The ioxaglate
formulation was 59% meglumine and sodium ioxaglate and
the diatrizoate formulation was a commercially available
76% diatrizoate formula (Renografin-76). The selection of
contrast agent was made according to a double blind ran-
domization scheme. Proper catheter position was confirmed
with a test injection of 8 to 14 cc of contrast agent followed
immediately by a 45 cc injection that was filmed.
Left and right ventricular pressures were measured at I,
2, 3, 4 and 5 minutes after the injection and arteriovenous
oxygen difference was measured at I, 3 and 5 minutes after
the injection. After completion of these measurements, se-
lective coronary arteriography was performed with the same
contrast agent used for left ventriculography.
Statistical analysis. The data were analyzed using dou-
ble-tailed Student's t tests for grouped data or paired data
where appropriate and the Wilcoxon two sample test. There
were no differences between the two groups of patients in
age, sex, body height and weight, final diagnosis and vol-
ume of contrast agent administered. Results are expressed
as mean values ± I standard error of the mean.
Results
Hemodynamic effects. The average hemodynamic val-
ues for the baseline determinations and the I, 2, 3, 4 and
5 minute postinjection determinations are tabulated in Table
I. Both agents produced a transient rise in left and right
ventricular end-diastolic pressures that peaked 3 minutes
after the injection and began to decline by the 5th minute.
Arteriovenous oxygen difference was also transiently de-
creased by both agents. Ioxaglate produced a significantly
smaller increase in left ventricular end-diastolic pressure
than did diatrizoate. The mean value for the rise of left
ventricular end-diastolic pressure in the ioxaglate group is
skewed upward by the inclusion of a single patient who
became agitated and developed a 30 mm Hg increase in left
ventricular systolic pressure after the injection. In addition,
the left ventricular end-diastolic pressure increased from 36
to 50 mm Hg. This patient's data are principally responsible
for the large standard error of the mean in the ioxaglate
group.
Seventeen of the 25 patients in the ioxaglate group de-
veloped a maximal increase of left ventricular end-diastolic
pressure of 4 mm Hg or less after the injection of the contrast
agent. Of the 25 patients who received diatrizoate, only 8
developed a left ventricular end-diastolic pressure increase
of 4 mm Hg or less and 14 developed an increase of 10 mm
Hg or more, compared with only 7 of 25 patients in the
ioxaglate group. The difference between the two groups in
the magnitude of the left ventricular end-diastolic pressure
increase is significant (probability [p] < 0.02).
Both agents increased right ventricular end-diastolic
pressure. The magnitudes of the changes were smaller and
the differences between the two groups, although similar to
those observed for left ventricular end-diastolic pressure,
were not as great (p < 0.1).
Both agents produced a decrease in arteriovenous oxygen
difference but the maximal decrease produced by ioxaglate
( - 0.33 ± 0.19 ml/IOO m!) was significantly less than
produced by diatrizoate (-0.85 ± 0.13 mlllOO ml) (p <
0.05).
The two groups did not differ in their baseline hemoglo-
bin concentrations (ioxaglate 15.21 ± 0.42 g/IOO ml, dia-
trizoate 15.20 ± 0.42 gllOO mI). Both agents produced
significant transient hemodilution as evidenced by a de-
crease in hemoglobin values. However, the maximal de-
crease in hemoglobin in the ioxaglate group was signifi-
cantly less than that in the diatrizoate group ( - 0.60 ± 0.09
vs. -0.82 ± 0.11 gllOO ml) (p < 0.05).
The time course and magnitude of the changes in hemo-
dynamics and hemodilution are illustrated in Figures I to
4, which plot the mean changes of the two groups in left
ventricular end-diastolic pressure, right ventricular end-dia-
stolic pressure, arteriovenous oxygen difference and hemo-
globin as a function of the time after injection. These figures
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Table 1. Hemodynamic Data Before and After Left Ventriculography (mean values ± standard error of the mean)
Diatrizoate Ioxaglate
Baseline I Min 2 Min 3 MIO 4 Min 5 Min Baseline I Min 2 Min 3 Min 4 Min 5 Min
LVSP (mm Hg) 136 130 138 138 138 144 132 136 139 140 138 137
±6 ±5.8 ±6.0 ±5.6 ±5.3 ±5.9 ±7 ±6.9 ±7.0 ±7.8 ±6.9 ±6.7
~LVSP (mm Hg) 4.4 3.8 5.0 7.2 7.2 4.4 7.3 7.4 7.2 5.0
±2.3 ±27 ±3.0 ±2.2 ±2.3 ±3.2 ±28 ±2.5 ±2.6 ±3.0
LVEDP (mm Hg) 13.8 20.7 22.0 22.2 21.6 21.6 15.0 18.3 20.6 19.1 18.3 18.9
±1.7 ±1.7 ± 1.8 ± 1.8 ± 1.8 ± 1.8 ± 1.6 ± 1.6 ± 1.9 ±1.7 ± 1.6 ±2.0
~LVEDP (mm Hg)* 6.8 9.2 9.5 8.7 77 33 5.3 4.0 3.3 3.9
±1.2 ±1.5 ± 1.5 ±1.5 ± 1.6 ±0.9 ±1.3 ± 1.0 ±0.9 ± 1.6
RVSP (mm Hg) 27.0 33.1 34.1 337 34.4 34.2 28.3 33.9 32.0 33.3 32.4 32.3
± 1.6 ±1.3 ±14 ± 16 ±1.5 ±1.5 ± 1.8 ±2.1 ±2.3 ±2.4 ±2.3 ±2.3
~RVSP (mm Hg)t 6.8 7.7 7.0 8.1 7.1 5.6 50 4.5 4.4 4.3
± 1.0 ±1.5 ±1.2 ±1.3 ±1.4 ±I ± 1.5 ±1.4 ±1.3 ±12
RVEDP (mm Hg) 66 9.0 9.2 9.2 9.9 9 I 6.4 8.3 8.1 8.0 7.9 7.9
±0.6 ±0.7 ±0.7 ±0.9 ±0.8 ±0.7 ±0.7 ±0.7 ±0.8 ±0.7 ±0.8 ±0.8
~RVEDP (mm Hg)t 2.5 2.9 2.9 3.4 2.5 1.9 2.1 1.6 1.5 1.5
±0.5 ±0.5 ±06 ±0.6 ±0.6 ±04 ±0.6 ±0.6 ±0.6 ±0.6
AV02D (mIIlOO ml) 5.15 4.30 4.40 4.63 5.02 4.69 4.84 4.94
±0.17 ±0.18 ±0.18 ±0.17 ±0.19 ±0.29 ±O 26 ±0.23
~AV02D (m1l100 mlr] -0.85 -0.75 -0.52 -0.33 -0.26 -014
±0.13 ±O 14 ±0.15 ±0.19 ±0.15 ±O.IO
*Diatrizoate group significantly different from ioxaglate group, p < 0.02. tDiatnzoate group not significantly different from ioxaglate group, p <
0.1. tDlatnzoate group significantly different from ioxaglate group, p < 0.05
AV02D = arteriovenous oxygen difference; ~AV02D = changes in artenovenous oxygen difference; ~LVEDP = changes 10 left ventricular end-
diastolic pressure; ~LVSP = changes in left ventricular systolic pressure; ~RVEDP = changes in nght ventricular end-diastolic pressure; ~RVSP =
changes in right ventncular systolic pressure; LVEDP = left ventricular end-diastolic pressure; LVSP = left ventncular systolic pressure; RVEDP =
right ventricular end-diastolic pressure; RVSP = right ventricular systolic pressure
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Figure 1. The time course of changes in left ventricular end-
diastolic pressure (~LVEDP) after left ventriculography with dia-
trizoate (triangles) or ioxaglate (circles) is shown. The bars rep-
resent ± I standard error of the mean.
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patients in whom rigid control of all factors affecting mea-
surements of hemodynamic variables could not be accom-
plished, it is not possible to distinguish between the obvious
difference in the osmolalities of the two agents and a pos-
sible difference between the two in direct myocardial action
Discussion
Ioxaglate versus diatrizoate contrast solutions. These
data demonstrate that left ventricular injection of a 59%
solution of sodium meglumine ioxaglate clearly produces
less hemodynamic disturbance and less hemodilution than
does injection of an identical volume of 66% meglumine,
10% sodium diatrizoate. Because the data were obtained in
demonstrate that the time course of the changes in these
variables produced by the two agents is similar, but that the
magnitude of changes produced by ioxaglate is less than
that of changes produced by diatrizoate.
Adverse effects. The incidence of adverse effects of the
two contrast agents was comparable. Three patients receiv-
ing ioxaglate experienced nausea and vomiting immediately
after the injection and three patients receiving diatrizoate
had similar episodes (p = not significant [NS]). One patient
receiving diatrizoate had an anaphylactic reaction that was
presumably caused by the contrast agent; this reaction was
successfully treated with fluids and epinephrine and no
residua occurred.
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Figure 2. The time course of changes in right ventricular end-
diastolic pressure (llRVEDP) afterleftventriculography with dia-
trizoate (triangles) or ioxaglate (circles) is shown. The bars rep-
resent ± I standard errorof the mean.
Figure 4. Thelime course of changes in whole blood hemoglobin
concentration after left ventriculography with diatrizoate (circles)
or ioxaglate (triangles) isshown. Thebars represent ± I standard
errorof the mean.
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Figure 3. The time course of changes in arteriovenous oxygen
difference (~AV02D) after left ventriculography with diatrizoate
(triangles) or ioxaglate (circles) is shown. The bars represent ±
I standard errorof the mean.
References
Gcnsim GG. Difiiorigt S. Myocardial toxicity of contrast agents used
In angiography. Radiology 1964;82:24-34.
2 Fnesmger GC. Schaffer 1. Cnley 1M. Gaertner RA. Ross RS. Hemo-
dynarruc consequences of the injection of radiopaque material. Cir-
culation 1965,31.730-40
3 Brown R. Rahimtoola SH. DaVIS GO. Swan H1C. The effect of an-
grocardiographic contrast medium on Circulatory dynamics In man
cardiac output dunng angiocardrography. Circulation 1965,3 I:234-40
4 Hamby RI. Amtabhan A. Wisoff GB. Hartstein ML. Effects of con-
trast medium on left ventricular pressure and volume With emphasis
on coronary artery disease Am Heart 1 1977.93:9-18
5 Gootman N. Rudolph AM. Buckley NM Effects of angiographrc
contrast media on cardiac function Am 1 Cardiol 1970.25.58-65.
6 Wolf G, Gerhngs E. Wilson W. Depressionof myocardialcontractility
Induced by hypertonic coronary injections In the isolated perfused dog
heart Radiology 1973;107:655-8.
7 Tragardh B. Lynch PR Cardiac function during left coronary arte-
riography In canines with ioxaglate, nomonic compounds, and dia-
tnzoate Invest Radiol 1980;15:449-51.
8 Lautrou 1. Bergin M. Cardinol A. Action of contrast media solutions
on cardiac hemodynamic parameters during coronary angiography in
the pig. Ann Radiol (Paris) 1978;21.261-5
9. Sovak M, Ranganathan R, Lang lH. Lasser EC. Concepts in design
of improved intravascular contrast agents. Ann Radiol (Paris)
1978.21 283-8
10. Higgms CB. Sovak M, Schmidt WS, Kelley Ml, Newell 10. Direct
myocardial effects of intracoronary administration of new contrast
matenals with low osmolality. Invest Radiol 1980;15:39-46.
We thank Thomas Tusing. MD and Donald Lankin of Malhnckrodt. Inc.
for <upplymg the ioxaglateused Inthis study We also thank Nancy Ferraro.
RN for technical support and Mary Ann Puentenueva for assistance in data
coordination and manuscript preparation
obvious clinical advantage, particularly when used in se-
riously ill patients who have abnormally elevated baseline
left ventricular filling pressures. It is likely that in such
patients, ioxaglate will allow a more extensive study to be
performed with less likelihood of precipitating unacceptable
hemodynamic changes.
I ~l~'"
·----1
1 IDIATRIZOATE
Vl'~
,------1
1
-08
-04
-02
!:.AVO;!)
Iml/lOOmil
-06
o
as a cause of the difference. Many studies of the effects of
X-ray contrast agents have demonstrated that the increase
in left ventricular filling pressure after injection is due both
to a direct depression of myocardial function and to the
acute expansion of intravascular volume caused by injection
of the hyperosmolar substance (1-8). Because the osmo-
lality of the ioxaglate preparation is so much lower than the
osmolality of the diatrizoate preparation and because the
diatrizoate preparation produced a substantially greater de-
crease in arteriovenous oxygen difference, it is likely that
the osmolality difference constitutes the major reason for
the difference we observed.
Clinical implications. These data indicate that ioxaglate
is a safe and effective contrast agent when used for left
ventriculography and coronary arteriography. The data fur-
ther demonstrate that the ioxaglate formula used produces
less hemodynamic disturbance than does a comparable vol-
ume of a diatrizoate formulation. This property confers an
